Pressmeddelande -
Affibody receives clinical milestone from Daiichi Sankyo
Solna, Sweden, December 1, 2015. Affibody AB announced today that it will receive a clinical milestone in connection with Daiichi Sankyo Company Limited’s (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568) initiation of a Phase I study.
Affibody and Daiichi Sankyo entered into a License Agreement regarding the Albumod™ platform in June, 2013. The Albumod™ platform extends the circulatory half-life of biopharmaceuticals leading to superior pharmacokinetics tailored to the disease state and increased patient compliance.
The molecule from this agreement has now entered into a Phase I study which triggers a predefined financial milestone to Affibody.
“The initiation of a clinical trial in our collaboration with Daiichi Sankyo is an important step for Affibody as collaborations are a key value driver for our company.”, says David Bejker, CEO of Affibody, “At the same time it further confirms the role of our platforms in drug discovery and development.”
Ämnen
- Hälsa, sjukvård, läkemedel
Kategorier
- collaboration agreement
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing. Affibody has ongoing commercial relationships with several companies including Abclon, Biotest, Daewoong, Daiichi Sankyo, GE, Medimmune, Nordic Nanovector, and Swedish Orphan Biovitrum.
Further information can be found at: www.affibody.com
